Judy Ellen Garber
Affiliation: Harvard University
- Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancersNadine Tung
Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Breast Cancer Res 12:R95. 2010....
- Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic featuresNadine Tung
Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Brookline Avenue, Boston, MA 02215, USA
Breast Cancer Res 12:R12. 2010..We undertook a study to assess the clinical factors that predict for an estrogen receptor positive (ER+) breast cancer in BRCA1 mutation carriers and to characterize the pathologic features of these tumors...
- Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriersEitan Friedman
The Suzanne Levy Gertner Oncogenetics Unit, The Chaim Sheba Medical Center, Tel Hashomer, Israel, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Breast Cancer Res 8:R15. 2006....
- Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriersSusan L Neuhausen
Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
Breast Cancer Res 11:R76. 2009..In this study, we investigate the association of variants in genes involved in IGF signaling and risk of breast cancer in women who carry deleterious BRCA1 and BRCA2 mutations...
- Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancerJudy E Garber
Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
J Natl Cancer Inst 102:942-9. 2010..We investigated whether FVL was associated with TE risk in women with early-stage breast cancer who took adjuvant tamoxifen...
- Hereditary cancer predisposition syndromesJudy E Garber
Dana Farber Cancer Institute, 44 Binney Street, SM 209, Boston, MA 02115, USA
J Clin Oncol 23:276-92. 2005..The prevalence, penetrance, tumor spectrum, and underlying genetic defects are discussed and summarized in a large table in which a more comprehensive enumeration of syndromes is provided...
- Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?Judith Balmana
Population Sciences Division, Dana Farber Cancer Institute, Smith 209, 44 Binney Street, 02115, Boston, MA 02115, USA
Breast Cancer Res Treat 92:273-7. 2005....
- The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapyMehra Golshan
Department of Surgery, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
Am J Surg 192:58-62. 2006..We sought to determine the frequency of BRCA1/BRCA2 mutations in women who underwent BCT. Genetic testing results were compared with the prior probability of mutations in either gene...
- A population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1/2 testingLisa Soleymani Lehmann
Massachusetts General Hospital, General Medicine Division, currently at Brigham and Women s Hospital, Division of General Medicine and Harvard Medical School, Division of Medical Ethics, Boston, Massachusetts 02115, USA
Genet Med 4:346-52. 2002..In particular, we assessed concerns about group discrimination, perceptions of the advantages and disadvantages of testing, and the relationship between concerns about discrimination and the potential benefits of genetic testing...
- Efficacy of neoadjuvant Cisplatin in triple-negative breast cancerDaniel P Silver
Dana Farber Cancer Institute, Department of Medical Oncology, Smith 209, 1 Jimmy Fund Way, Boston, MA 02115, USA
J Clin Oncol 28:1145-53. 2010..CONCLUSION Single-agent cisplatin induced response in a subset of patients with TNBC. Decreased BRCA1 expression may identify subsets of TNBCs that are cisplatin sensitive. Other biomarkers show promise in predicting cisplatin response...
- Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reductionMichael J Callahan
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women s Hospital, Boston, MA 02115, USA
J Clin Oncol 25:3985-90. 2007..To review the frequency and location of malignancies detected after prophylactic salpingo-oophorectomy in women with BRCA mutations...
- Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissuesPamela S Larson
Department of Pathology and Laboratory Medicine and Medicine, Boston University School of Medicine, Boston, MA 02118, USA
J Clin Oncol 23:8613-9. 2005..Normal-appearing breast epithelium can contain genetic abnormalities, including allele imbalance (AI), also referred to as loss of heterozygosity. Whether abnormalities are associated with cancer or cancer risk is unknown...
- Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilizationDouglas E Levy
Institute for Health Policy, Massachusetts General Hospital, 50 Staniford St, Suite 901, Boston, MA 02114, USA
J Gen Intern Med 24:822-8. 2009..BRCA1/2 testing is one of the most well-established genetic tests to predict cancer risk. Guidelines are available to help clinicians determine who will benefit most from testing...
- Breast cancer prevention: patient decision making and risk communication in the high risk settingElissa M Ozanne
Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Breast J 16:38-47. 2010....
- Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancersLaura C Collins
Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
Am J Surg Pathol 33:1093-7. 2009..However, whether or not expression of biomarkers characteristic of basal-like breast cancers helps to define a subset of women with triple-negative breast cancers who are likely to harbor BRCA1 mutations is an unresolved issue...
- Physicians' experiences with BRCA1/2 testing in community settingsNancy L Keating
Division of General Internal Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
J Clin Oncol 26:5789-96. 2008....
- Support needs and acceptability of psychological and peer consultation: attitudes of 108 women who had undergone or were considering prophylactic mastectomyANDREA F PATENAUDE
Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA andrea
Psychooncology 17:831-43. 2008..This retrospective, cross-sectional study explored interest in and acceptability of psychological consultation for issues related to PM among 108 women who had undergone or were considering surgery...
- Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancerAnn K Folkins
Divisionsof Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
Gynecol Oncol 115:108-11. 2009..Many ovarian carcinomas are presumed to arise within ovarian cortical inclusion cysts (CICs). This study examined the frequency of ovarian CICs in relation to epidemiologic risk factors in women with BRCA1 and BRCA2 (BRCA+) mutations...
- Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688delArcangela De Nicolo
Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer Res 69:7030-7. 2009..Multimodal analyses like ours could advance understanding of tumor suppression by BRCA1 and ultimately contribute to developing efficient strategies for screening and characterization of VUS...
- Complementary and alternative medicine use among women with breast cancerLisa M DiGianni
Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 20:34S-8S. 2002..A common theme seen in many studies is that CAM use in women with breast cancer is highly correlated with increased psychosocial distress...
- Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndromePatricia Wong
Department of Internal Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
Gastroenterology 130:73-9. 2006..We investigated the prevalence of early onset colorectal cancer and the frequency of p53 germline mutations in 64 families from a Li-Fraumeni syndrome (LFS) registry...
- Accuracy of cancer family histories: comparison of two breast cancer syndromesKatherine A Schneider
Population Sciences, Dana Farber Cancer Institute, Boston, MA 02115, USA
Genet Test 8:222-8. 2004..Our data suggest that it may not be necessary to confirm breast cancer diagnoses routinely; however, documentation of other cancer types remains important for appropriate risk assessment and follow-up...
- BRCA1/2 genetic testing in the community settingWendy Y Chen
Department of Adult Oncology, Dana Farber Cancer Institute, and Channing Laboratory, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
J Clin Oncol 20:4485-92. 2002..This study evaluates the process and early outcomes of BRCA1/2 genetic testing as a clinical service in the community setting...
- Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tellAndrea Farkas Patenaude
Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 24:700-6. 2006..This study identifies factors predicting patterns of disclosure of BRCA1/2 test results to first-degree relatives (FDRs) among women tested in a clinical protocol...
- Complementary medicine use among women enrolled in a genetic testing programLisa M DiGianni
Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Epidemiol Biomarkers Prev 12:321-6. 2003..Any potential effects of the genetic information itself on CAM use, and any possible relationship of CAM use to other risk reduction behaviors, require further research...
- Complementary medicine use before and 1 year following genetic testing for BRCA1/2 mutationsLisa M DiGianni
Dana Farber Cancer Institute, 44 Binney Street, SM228, Boston, MA 02115, USA
Cancer Epidemiol Biomarkers Prev 15:70-5. 2006..We explored change in complementary and alternative medicine (CAM) use by unaffected women and cancer survivors from enrollment into a randomized BRCA1/2 testing program to CAM use 1 year following results disclosure...
- Ethical issues in cancer genetics: I 1) whose information is it?Katherine A Schneider
Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, SM331, Boston, MA 02115, USA
J Genet Couns 15:491-503. 2006..e. duty to warn). We also provide a summary of consensus points and additional discussion questions for each case...
- The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndromeFabiola Medeiros
Division of Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
Am J Surg Pathol 30:230-6. 2006..Investigative strategies targeting the fimbriated end of the fallopian tube should further define its role in the pathogenesis of familial and sporadic ovarian serous carcinomas...
- F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndromeSerena Masciari
Division of Population Sciences, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
JAMA 299:1315-9. 2008..The diversity of tumors and rarity of families have contributed to the difficulty in devising effective screening recommendations for members of LFS kindreds...
- A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutationsAnn K Folkins
The Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
Gynecol Oncol 109:168-73. 2008..This study compared the prevalence of p53 signatures in ovarian cortical inclusion cysts (CICs) and fallopian tubes from BRCA+ women and explored their relationship...
- Molecular definition of breast tumor heterogeneityMichail Shipitsin
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer Cell 11:259-73. 2007..Our data suggest prognostic relevance of CD44+ cells and therapeutic targeting of distinct tumor cell populations...
- Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindredFrederick P Li
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 23:2735-43. 2005..A tumor from the proband was analyzed to compare features with sporadic GISTs...
- Progress in the management of gynecologic cancer: consensus summary statementStephen A Cannistra
Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
J Clin Oncol 21:129s-132s. 2003
- Male patients with diagnoses of both breast cancer and prostate cancerStacey B Leibowitz
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Breast J 9:208-12. 2003..In addition, these men do not appear to develop prostate cancer at an earlier age or more aggressive stage than the general population...
- Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancerHarold J Burstein
Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 64:496-504. 2006..To evaluate the safety and feasibility of concurrent radiation therapy and paclitaxel-based adjuvant chemotherapy, given either weekly or every 3 weeks, after adjuvant doxorubicin and cyclophosphamide (AC)...
- VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapyHarold J Burstein
Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Clin Cancer Res 14:7871-7. 2008....
- Breast MRI wire-guided excisional biopsy: specimen size as compared to mammogram wire-guided excisional biopsy and implications for useSara H Javid
Department of Surgery, Brigham and Women s Hospital, Boston, MA, USA
Ann Surg Oncol 14:3352-8. 2007..We hypothesized that more tissue would be resected with MRIbx compared to Mammobx. We also sought to evaluate factors that might predict the presence of breast cancer in patients undergoing MRIbx...
- Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?Davendra Segara
Department of Surgery, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Surg Oncol 96:474-80. 2007..The purpose of this study is to review imaging studies performed in patients who received preoperative chemotherapy prior to surgery and determine whether MRI, ultrasound (US) or physical exam best predicted final pathologic tumor size...
- Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessonsHarold J Burstein
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Clin Breast Cancer 7:158-61. 2006..We believe clinicians should be aware of the potential ovarian reserve among women with treatment-related amenorrhea so as to avoid use of AI therapy in patients in whom there is uncertainty about menopausal status...
- Prophylactic oophorectomy and hormone replacement therapy: protection at what price?Judy Ellen Garber
J Clin Oncol 22:978-80. 2004
- Time to check CHEK2 in families with breast cancer?Kenneth Offit
J Clin Oncol 26:519-20. 2008
- Epidemiology of Syndromic GI Stromal TumorsJudy Garber; Fiscal Year: 2007..Our goal is to define the spectrum of syndromic GISTs, and to generate the information that will form the basis for clinical counseling for members of GIST kindreds, with and without germline mutations in KIT or PDGFRA. ..
- Process & Outcomes of BRCAL/2 clinical testingJudy Garber; Fiscal Year: 2003..The information learned from this project may help to create a standard for the optimal conduct of BRCA 1/2 testing, and potentially for other predisposition testing as well. ..
- BREAST CANCER PREVENTION IN HODGKINS DISEASEJudy Garber; Fiscal Year: 2002..We will also evaluate mammographic density as a potential intermediate endpoint that might permit more rapid completion of a randomized study. ..
- RANDOMIZED STUDY--BRCA1/2 GENETIC V CONSENT COUNSELINGJudy Garber; Fiscal Year: 2001..These include participant genetics knowledge, anxiety, interest in testing, satisfaction with the testing process and decision making. They will also compare the health care costs associated with both interventions and health behaviors. ..
- Epidemiology of Syndromic GI Stromal TumorsJudy Ellen Garber; Fiscal Year: 2010..Our goal is to define the spectrum of syndromic GISTs, and to generate the information that will form the basis for clinical counseling for members of GIST kindreds, with and without germline mutations in KIT or PDGFRA. ..